<DOC>
	<DOCNO>NCT00704756</DOCNO>
	<brief_summary>This observational study patient undergo treatment PegIntron Rebetol chronic hepatitis C clinical practice Belgium . Treatment administer part study . Safety parameter assess retrospectively . Efficacy parameter , relapse rate sustain virologic response rate , assess prospectively . The objective study examine association safety , virologic , histologic , demographic parameter patient outcome ( relapse rate sustain virologic response rate ) .</brief_summary>
	<brief_title>An Observational Study Patients With Chronic Hepatitis C Undergoing Treatment With PegIntron Rebetol Clinical Practice Belgium ( Study P05494 ) ( WITHDRAWN )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Male female adult ( 18 year old ) subject treat physician decide start treatment PegIntron® Rebetol® reach EndofTreatment time point . For prospective component , evidence treatment response EOT complete course therapy per SmPC . Subjects must demonstrate willingness participate study comply procedure sign write informed consent . Subjects must diagnose chronic hepatitis C ( genotypes 1 , 2 , 3 , 4 , 5 6 ) . Subjects must free clinically significant disease would interfere study participation . For prospective component study : patient achieve EndofTreatment response complete course therapy per SmPC .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>